Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 2
2005 2
2006 4
2008 2
2009 2
2010 4
2011 2
2012 2
2013 5
2014 2
2016 5
2017 6
2019 1
2020 5
2021 5
2022 6
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine.
Afferi L, Spahn M, Hayoz S, Strebel RT, Rothschild SI, Seifert H, Özdemir BC, Kiss B, Maletzki P, Engeler D, Wirth G, Hadaschik B, Lucca I, John H, Sauer A, Müntener M, Bubendorf L, Schneider M, Musilova J, Petrausch U, Cathomas R; Swiss Group for Clinical Cancer Research (SAKK). Afferi L, et al. Among authors: schneider m. BJU Int. 2024 Mar 8. doi: 10.1111/bju.16318. Online ahead of print. BJU Int. 2024. PMID: 38456541
The comorbidity profiles and medication issues of patients with multiple system atrophy: a systematic cross-sectional analysis.
Ye L, Greten S, Wegner F, Doll-Lee J, Krey L, Heine J, Gandor F, Vogel A, Berger L, Gruber D, Levin J, Katzdobler S, Peters O, Dashti E, Priller J, Spruth EJ, Kühn AA, Krause P, Spottke A, Schneider A, Beyle A, Kimmich O, Donix M, Haussmann R, Brandt M, Dinter E, Wiltfang J, Schott BH, Zerr I, Bähr M, Buerger K, Janowitz D, Perneczky R, Rauchmann BS, Weidinger E, Düzel E, Glanz W, Teipel S, Kilimann I, Wurster I, Brockmann K, Hoffmann DC, Klockgether T, Krause O, Heck J; PROMESA study group; Höglinger GU, Klietz M. Ye L, et al. J Neurol. 2024 May;271(5):2639-2648. doi: 10.1007/s00415-024-12207-5. Epub 2024 Feb 14. J Neurol. 2024. PMID: 38353748
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.
Mark M, Froesch P, Gysel K, Rothschild SI, Addeo A, Ackermann CJ, Chiquet S, Schneider M, Ribi K, Maranta AF, Bastian S, von Moos R, Joerger M, Früh M; Swiss Group for Clinical Cancer Research (SAKK). Mark M, et al. Among authors: schneider m. Eur J Cancer. 2024 Mar;200:113600. doi: 10.1016/j.ejca.2024.113600. Epub 2024 Feb 5. Eur J Cancer. 2024. PMID: 38330766 Free article. Clinical Trial.
A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults†.
McMahon R, Fuchs U, Schneider M, Hadl S, Hochreiter R, Bitzer A, Kosulin K, Koren M, Mader R, Zoihsl O, Wressnigg N, Dubischar K, Buerger V, Eder-Lingelbach S, Jaramillo JC. McMahon R, et al. Among authors: schneider m. J Travel Med. 2024 Mar 1;31(2):taad156. doi: 10.1093/jtm/taad156. J Travel Med. 2024. PMID: 38091981 Free PMC article. Clinical Trial.
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
Cathomas R, Rothschild SI, Hayoz S, Bubendorf L, Özdemir BC, Kiss B, Erdmann A, Aeppli S, Mach N, Strebel RT, Hadaschik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Schneider M, Musilova J, Spahn M, Petrausch U. Cathomas R, et al. Among authors: schneider m. J Clin Oncol. 2023 Nov 20;41(33):5131-5139. doi: 10.1200/JCO.23.00363. Epub 2023 Aug 17. J Clin Oncol. 2023. PMID: 37590894 Clinical Trial.
Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.
Schneider M, Narciso-Abraham M, Hadl S, McMahon R, Toepfer S, Fuchs U, Hochreiter R, Bitzer A, Kosulin K, Larcher-Senn J, Mader R, Dubischar K, Zoihsl O, Jaramillo JC, Eder-Lingelbach S, Buerger V, Wressnigg N. Schneider M, et al. Lancet. 2023 Jun 24;401(10394):2138-2147. doi: 10.1016/S0140-6736(23)00641-4. Epub 2023 Jun 12. Lancet. 2023. PMID: 37321235 Free PMC article. Clinical Trial.
Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy - protocol of a multicentre, single arm phase 2 trial (SAKK 06/19).
Petrausch U, Spahn M, Schneider M, Hayoz S, Rentsch CA, Rothschild S, Omlin A, Cathomas R. Petrausch U, et al. Among authors: schneider m. BMJ Open. 2023 Jun 7;13(6):e067634. doi: 10.1136/bmjopen-2022-067634. BMJ Open. 2023. PMID: 37286312 Free PMC article.
Corrigendum to 'Substances from unregulated drug markets - A retrospective data analysis of customer-provided samples from a decade of drug checking service in Zurich (Switzerland)' [Volume 114, April 2023, 103972].
Magnolini R, Schneider M, Schori D, Trachsel D, Bruggmann P. Magnolini R, et al. Among authors: schneider m. Int J Drug Policy. 2023 Jun;116:104022. doi: 10.1016/j.drugpo.2023.104022. Epub 2023 Apr 17. Int J Drug Policy. 2023. PMID: 37075627 Free article. No abstract available.
64 results